TEVA-TOBRAMYCIN DIN 02389622
Status: Marketed
Holder: TEVA CANADA LIMITED
Molecule: TOBRAMYCIN (TOBRAMYCIN SULFATE)
Available to quote
Health Canada record
| Active ingredient(s) | TOBRAMYCIN (TOBRAMYCIN SULFATE) 60 MG |
|---|---|
| Dosage form | Solution |
| Route | Inhalation |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01GB01 TOBRAMYCIN |
| Original market date | 03-Feb-2016 |
| Current status date | 03-Feb-2016 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TOBRAMYCIN (TOBRAMYCIN SULFATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02239630 | TOBI | BGP PHARMA ULC | Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 300 MG | Marketed |
| 00533688 | TOBRAMYCIN FOR INJECTION | FRESENIUS KABI CANADA LTD | Powder For Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 1.2 G | Marketed |
| 02457563 | TOBRAMYCIN INHALATION SOLUTION USP | LABORATOIRE RIVA INC. | Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 300 MG | Approved |
| 02533103 | TOBRAMYCIN INJECTION USP | JAMP PHARMA CORPORATION | Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG | Marketed |
| 02241209 | TOBRAMYCIN INJECTION USP | SANDOZ CANADA INCORPORATED | Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 10 MG | Marketed |
| 02241210 | TOBRAMYCIN INJECTION USP | SANDOZ CANADA INCORPORATED | Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG | Marketed |
| 02502364 | TOBRAMYCIN INJECTION USP | STERIMAX INC | Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 10 MG | Approved |
| 02502372 | TOBRAMYCIN INJECTION USP | STERIMAX INC | Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG | Marketed |
| 02230640 | TOBRAMYCIN INJECTION, USP | FRESENIUS KABI CANADA LTD | Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG | Marketed |
| 02420287 | JAMP-TOBRAMYCIN | JAMP PHARMA CORPORATION | Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG | Cancelled Post Market |
| 00325457 | NEBCIN INJ 10MG/ML | ELI LILLY CANADA INC | Liquid | TOBRAMYCIN (TOBRAMYCIN SULFATE) 10 MG | Cancelled Post Market |
| 00851825 | NEBCIN INJ 10MG/ML (VANTAGE VIAL) | ELI LILLY CANADA INC | Liquid | TOBRAMYCIN (TOBRAMYCIN SULFATE) 10 MG | Cancelled Post Market |
| 00325449 | NEBCIN INJ 40MG/ML | ELI LILLY CANADA INC | Liquid | TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG | Cancelled Post Market |
| 00375764 | NEBCIN INJ 60MG | ELI LILLY CANADA INC | Liquid | TOBRAMYCIN (TOBRAMYCIN SULFATE) 60 MG | Cancelled Post Market |
| 00381969 | NEBCIN INJ 80MG | ELI LILLY CANADA INC | Liquid | TOBRAMYCIN (TOBRAMYCIN SULFATE) 80 MG | Cancelled Post Market |
| 02285150 | TOBRAMYCIN FOR INJECTION USP | STERIMAX INC | Powder For Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 1.2 G | Dormant |
| 02443368 | TOBRAMYCIN INHALATION SOLUTION | SANDOZ CANADA INCORPORATED | Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 300 MG | Cancelled Post Market |
| 02230639 | TOBRAMYCIN INJECTION | FRESENIUS KABI CANADA LTD | Solution | TOBRAMYCIN (TOBRAMYCIN SULFATE) 10 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 13484 | 2012-07-12 | Abbreviated New Drug Submission (ANDS) |